Experts Identified Clinical Steps for Psoriasis Treatment
Dermatologists clarified diagnostic and procedural pathways to address biologic treatment failure in patients.
Updated on Sept. 24, 2026 in Heart Disease
Live Poll
Should patients investigate treatment adherence before assuming their medication has stopped working?
Clinical experts have identified a systematic approach to managing psoriasis treatment failure by distinguishing between primary non-response and secondary loss of efficacy. The guidance emphasizes investigating patient adherence, dosing, and distribution before altering therapeutic strategies.
Why it matters
Clinicians must effectively differentiate between drug inefficacy, poor medication adherence, and incorrect diagnoses to avoid unnecessary treatment changes. Accurate identification of these factors ensures that patients receive appropriate interventions rather than ineffective therapy swaps.
A Brazilian study found that distribution problems increased the risk for biologic treatment discontinuation by 45% among 166 patients. Meanwhile, a Japanese study demonstrated that deucravacitinib reduced PASI and DLQI scores over 104 weeks.
The players
Brazilian Congress of Dermatology
This is a professional medical association that hosts an annual forum for experts to discuss advancements and challenges in skin disease treatment.
BIOREP
This is a multinational medical registry that compiles long-term data on biologic treatments for dermatological conditions in the Czech Republic and Slovakia.
The details
Before modifying a patient's therapeutic regimen, dermatologists are advised to assess potential dispensing interruptions, adherence, and dosing frequency. Professionals should also use antidrug antibody testing to rule out immunogenicity and consider that structural joint damage may sometimes be mislabeled as persistent inflammatory disease activity.
Timeline
September 10, 2026: The 79th Brazilian Congress of Dermatology was held in Fortaleza.
January 2015 to June 2025: Data collection occurred for the BIOREP registry.
Health Landscape
This research follows a pattern of analysis established by the BIOREP registry for tracking longitudinal treatment outcomes. Such findings shift the focus from simple drug efficacy to the complex logistical and diagnostic barriers that define patient success in chronic care.
Patients experiencing persistent symptoms should consult their dermatologist to evaluate if these issues stem from logistical dispensing barriers or incorrect dosing. This process can help ensure that treatment adjustments are based on specific medical evidence rather than misdiagnosed drug resistance.
The takeaway
Effective psoriasis management requires a careful diagnostic review before switching biologics to ensure that environmental or adherence factors are not the primary cause of failure. Patients should maintain open communication with their care team regarding any gaps in medication access or administration.
Further reading
Learn more about managing chronic conditions and care protocols in the Heart Disease section.
Source note: This article includes information reported by Medscape.
Live Poll
Should patients investigate treatment adherence before assuming their medication has stopped working?
